This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Celanese's (CE) Q1 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Celanese (CE) witnesses increased volumes due to an additional month of sales from the Mobility & Materials acquisition as well as demand recovery in Europe and Asia in Q1.
Celanese (CE) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Celanese (CE) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Celanese (CE) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Celanese (CE) delivered earnings and revenue surprises of 21.08% and 4.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Stocks Enter Sixth Week of Low Volatility as Earnings Beat Expectations
by Mayur Thaker
April jobs beat expectations, but primary economic trends remain bearish.
Celanese (CE) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Celanese (CE) is likely to have gained from pricing and productivity actions amid headwinds from higher input costs and destocking in Q1.
DOW Selects Linde for Ethylene Cracker and Derivatives Site
by Zacks Equity Research
The ethylene cracker and derivatives complex will decarbonize roughly 20% of Dow's (DOW) global ethylene capacity while increasing its global polyethylene supply by around 15%.
Air Products (APD) to Build Hydrogen Refueling Station in Alberta
by Zacks Equity Research
The hydrogen refueling station will be Air Products' (APD) first in Canada. It will also be Alberta's first commercial-scale hydrogen refueling station.
Celanese (CE) Up 24% in 6 Months: What's Driving the Stock?
by Zacks Equity Research
Celanese (CE) gains on cost and productivity actions, investments in high-return projects and contributions of acquisitions.
Celanese (CE) & Glaukos Join Forces for Glaucoma Treatment
by Zacks Equity Research
Celanese (CE) partners with Glaukos to provide VitalDose for sustained release treatment for glaucoma.
Is Invesco S&P 500 Equal Weight Materials ETF (RTM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RTM
Is First Trust Large Cap Value AlphaDEX ETF (FTA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FTA
Here's Why You Should Retain Celanese (CE) in Your Portfolio
by Zacks Equity Research
Celanese (CE) gains on productivity actions, investments in high-return organic projects and synergies of acquisitions.
Is First Trust Large Cap Core AlphaDEX ETF (FEX) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FEX
Should You Invest in the Invesco S&P 500 Equal Weight Materials ETF (RTM)?
by Zacks Equity Research
Sector ETF report for RTM
Should First Trust Large Cap Core AlphaDEX ETF (FEX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FEX
Is First Trust Multi Cap Value AlphaDEX ETF (FAB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FAB
Should First Trust Large Cap Value AlphaDEX ETF (FTA) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTA
Celanese (CE) Partners With Alessa for Drug Delivery System
by Zacks Equity Research
Celanese (CE) forms an alliance with Alessa Therapeutics to develop an innovative drug delivery system for oncology patients.
Celanese (CE) & Mitsui Ink New Partnership, Extend Fairway JV
by Zacks Equity Research
Celanese (CE) joins forces with Mitsui to form a new Food Ingredient joint venture to strengthen its strategic partnership with the latter.
Celanese's (CE) Earnings and Revenues Miss Estimates in Q4
by Zacks Equity Research
Input cost inflation, supply chain disruptions and consumer destocking weigh on fourth-quarter performance of Celanese (CE).
Celanese (CE) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Celanese (CE) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Celanese (CE) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Celanese (CE) delivered earnings and revenue surprises of -7.69% and 2.77%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Stocks Jittery With Pesky Inflation and Weak Economic Data
by Mayur Thaker
EPS Estimate revisions, inflation and unemployment are the trifecta to solving the market's next move.
Celanese (CE) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Softness in demand in Europe & Asia, weaker volumes and elevated energy & logistic cost are expected to have put a dent in Celanese's (CE) Q4 performance.
AdvanSix (ASIX) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
AdvanSix (ASIX) delivered earnings and revenue surprises of -18.59% and 14.51%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?